| scholarly article | Q13442814 |
| P50 | author | Ellie Azure Frost | Q91963188 |
| P2093 | author name string | Chengwen Li | |
| R Jude Samulski | |||
| Zheng Chai | |||
| Xintao Zhang | |||
| Amanda Lee Dobbins | |||
| P2860 | cites work | The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy. | Q24533492 |
| Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy | Q24535690 | ||
| Adeno-associated virus type 2 VP2 capsid protein is nonessential and can tolerate large peptide insertions at its N terminus | Q24563214 | ||
| Cross-dressing the virion: the transcapsidation of adeno-associated virus serotypes functionally defines subgroups | Q24623923 | ||
| Site-directed mutagenesis of adeno-associated virus type 2 structural protein initiation codons: effects on regulation of synthesis and biological activity | Q24649913 | ||
| A comprehensive review of retinal gene therapy | Q27023914 | ||
| Creation of a mouse expressing defective human factor IX | Q28585072 | ||
| Comparative analysis of adeno-associated virus capsid stability and dynamics | Q30557598 | ||
| The VP1 capsid protein of adeno-associated virus type 2 is carrying a phospholipase A2 domain required for virus infectivity | Q34124491 | ||
| AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. | Q34168942 | ||
| Selective in vivo targeting of human liver tumors by optimized AAV3 vectors in a murine xenograft model | Q34729878 | ||
| Analysis of AAV serotypes 1-9 mediated gene expression and tropism in mice after systemic injection | Q34770058 | ||
| Long-term safety and efficacy of factor IX gene therapy in hemophilia B. | Q34783922 | ||
| Terminal N-linked galactose is the primary receptor for adeno-associated virus 9. | Q34787342 | ||
| X-linked thrombophilia with a mutant factor IX (factor IX Padua). | Q35008970 | ||
| Adenovirus-associated virus vector-mediated gene transfer in hemophilia B | Q35691659 | ||
| Intracellular trafficking of adeno-associated viral vectors. | Q36097743 | ||
| Rapid uncoating of vector genomes is the key to efficient liver transduction with pseudotyped adeno-associated virus vectors | Q36509889 | ||
| Strategies to generate high-titer, high-potency recombinant AAV3 serotype vectors | Q36867801 | ||
| Engraftment of a galactose receptor footprint onto adeno-associated viral capsids improves transduction efficiency | Q37213826 | ||
| Adeno-associated virus serotypes for gene therapeutics. | Q38570101 | ||
| Application of polyploid adeno-associated virus vectors for transduction enhancement and neutralizing antibody evasion | Q38645275 | ||
| In vivo tissue-tropism of adeno-associated viral vectors | Q38824171 | ||
| Gene therapy for the CNS using AAVs: The impact of systemic delivery by AAV9. | Q38956595 | ||
| Stability and compatibility of recombinant adeno-associated virus under conditions commonly encountered in human gene therapy trials | Q39024016 | ||
| Unique characteristics of AAV1, 2, and 5 viral entry, intracellular trafficking, and nuclear import define transduction efficiency in HeLa cells. | Q39406314 | ||
| Structure and dynamics of adeno-associated virus serotype 1 VP1-unique N-terminal domain and its role in capsid trafficking | Q39792135 | ||
| Assembly of viruslike particles by recombinant structural proteins of adeno-associated virus type 2 in insect cells | Q40061611 | ||
| Surface-exposed adeno-associated virus Vp1-NLS capsid fusion protein rescues infectivity of noninfectious wild-type Vp2/Vp3 and Vp3-only capsids but not that of fivefold pore mutant virions | Q40132033 | ||
| Nucleotide sequence and organization of the adeno-associated virus 2 genome | Q40143539 | ||
| Comparison of the ability of adeno-associated viral vectors pseudotyped with serotype 2, 5, and 8 capsid proteins to mediate efficient transduction of the liver in murine and nonhuman primate models | Q40418515 | ||
| Electron cryo-microscopy and image reconstruction of adeno-associated virus type 2 empty capsids | Q41630679 | ||
| Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes | Q42739394 | ||
| Endocytic processing of adeno-associated virus type 8 vectors for transduction of target cells | Q45357434 | ||
| First AAV gene therapy poised for landmark approval | Q45874199 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 12 | |
| P577 | publication date | 2019-12-09 | |
| P1433 | published in | Viruses | Q7935305 |
| P1476 | title | Chimeric Capsid Proteins Impact Transduction Efficiency of Haploid Adeno-Associated Virus Vectors | |
| P478 | volume | 11 |
| Q99559716 | Bound Protein and Peptide-Based Strategies for Adeno-associated Virus Vector-Mediated Gene Therapy: Where do We Stand Now? | cites work | P2860 |
Search more.